Please use this identifier to cite or link to this item:
https://hdl.handle.net/10316/107081
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Calmeiro, João | - |
dc.contributor.author | Carrascal, Mylène A. | - |
dc.contributor.author | Gomes, Célia | - |
dc.contributor.author | Falcão, Amílcar C. | - |
dc.contributor.author | Cruz, Maria Teresa | - |
dc.contributor.author | Neves, Bruno Miguel | - |
dc.date.accessioned | 2023-05-11T11:35:45Z | - |
dc.date.available | 2023-05-11T11:35:45Z | - |
dc.date.issued | 2019-09-04 | - |
dc.identifier.issn | 2051-1426 | pt |
dc.identifier.uri | https://hdl.handle.net/10316/107081 | - |
dc.description.abstract | Dendritic cells (DCs) are central players in the immune system, with an exquisite capacity to initiate and modulate immune responses. These functional characteristics have led to intense research on the development of DC-based immunotherapies, particularly for oncologic diseases. During recent decades, DC-based vaccines have generated very promising results in animal studies, and more than 300 clinical assays have demonstrated the safety profile of this approach. However, clinical data are inconsistent, and clear evidence of meaningful efficacy is still lacking. One of the reasons for this lack of evidence is the limited functional abilities of the used ex vivo-differentiated DCs. Therefore, alternative approaches for targeting and modulating endogenous DC subpopulations have emerged as an attractive concept. Here, we sought to revise the evolution of several strategies for the in situ mobilization and modulation of DCs. The first approaches using chemokine-secreting irradiated tumor cells are addressed, and special attention is given to the cutting-edge injectable bioengineered platforms, programmed to release chemoattractants, tumor antigens and DC maturating agents. Finally, we discuss how our increasing knowledge of DC biology, the use of neoantigens and their combination with immune checkpoint inhibitors can leverage the refinement of these polymeric vaccines to boost their antitumor efficacy. | pt |
dc.language.iso | eng | pt |
dc.publisher | BMJ Publishing Group | pt |
dc.rights | openAccess | pt |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | pt |
dc.subject | Biomaterial-based scaffolds | pt |
dc.subject | Dendritic cells | pt |
dc.subject | In situ mobilization | pt |
dc.subject | Antitumor immunotherapy | pt |
dc.subject.mesh | Animals | pt |
dc.subject.mesh | Biocompatible Materials | pt |
dc.subject.mesh | Cancer Vaccines | pt |
dc.subject.mesh | Dendritic Cells | pt |
dc.subject.mesh | Humans | pt |
dc.subject.mesh | Immunotherapy | pt |
dc.subject.mesh | Neoplasms | pt |
dc.subject.mesh | Cellular Reprogramming | pt |
dc.subject.mesh | Drug Delivery Systems | pt |
dc.title | Biomaterial-based platforms for in situ dendritic cell programming and their use in antitumor immunotherapy | pt |
dc.type | article | - |
degois.publication.firstPage | 238 | pt |
degois.publication.issue | 1 | pt |
degois.publication.title | Journal for ImmunoTherapy of Cancer | pt |
dc.peerreviewed | yes | pt |
dc.identifier.doi | 10.1186/s40425-019-0716-8 | pt |
degois.publication.volume | 7 | pt |
dc.date.embargo | 2019-09-04 | * |
uc.date.periodoEmbargo | 0 | pt |
item.fulltext | Com Texto completo | - |
item.grantfulltext | open | - |
item.languageiso639-1 | en | - |
item.cerifentitytype | Publications | - |
item.openairetype | article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
crisitem.author.researchunit | CNC - Center for Neuroscience and Cell Biology | - |
crisitem.author.orcid | 0000-0002-7497-4129 | - |
crisitem.author.orcid | 0000-0002-3854-6549 | - |
crisitem.author.orcid | 0000-0001-9846-6754 | - |
Appears in Collections: | FFUC- Artigos em Revistas Internacionais I&D CNC - Artigos em Revistas Internacionais I&D ICBR - Artigos em Revistas Internacionais I&D CIBB - Artigos em Revistas Internacionais I&D CIBIT - Artigos em Revistas Internacionais |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Biomaterialbased-platforms-for-in-situ-dendritic-cell-programming-and-their-use-in-antitumor-immunotherapyJournal-for-ImmunoTherapy-of-Cancer.pdf | 1.16 MB | Adobe PDF | View/Open |
SCOPUSTM
Citations
34
checked on Sep 30, 2024
WEB OF SCIENCETM
Citations
30
checked on Sep 2, 2024
Page view(s)
87
checked on Sep 24, 2024
Download(s)
32
checked on Sep 24, 2024
Google ScholarTM
Check
Altmetric
Altmetric
This item is licensed under a Creative Commons License